Therapy Areas: Cardiovascular
BioCardia wins two new US patents to develop cardiac cell therapies
17 September 2018 -

Cardiovascular regenerative therapy company BioCardia Inc (OTC:BCDA) reported on Friday the receipt of two patents in the US covering the methods of preparing mesenchymal stem cell therapy for the treatment of heart failure as well as the transradial delivery of biotherapeutic agents to the heart.

The first US Patent No. 10,035,982, which relates to methods of preparing culture-expanded cells for the treatment of heart failure, has broad claims on an approach for expanding mesenchymal stem cells in media derived from the blood of the same donor who has provided the source cells for culture expansion. A single donor provides the source cells for expansion of the targeted stem cells and blood over time to produce a donor-specific culture medium, added the company.

Under the first patent, the claimed method may provide a solution to the risks and potential immune reactions associated with cells manufactured utilizing culture media derived from animal and human sources,according to the company.

Additionally, the company's US second Patent No. 10,071,226, which describes a system for delivery of biotherapeutic agents to the heart, claims a catheter system may be used to achieve heart access from the radial artery in a patient's wrist and then advanced into a chamber of the heart to directly deliver biologic therapies.

In the second patent, the patients can receive cardiac cell therapy in an outpatient setting and return home immediately following the procedure with only a small bandage on their wrist. This system could reduce the cost to the healthcare system and appeal to patients, physicians, hospital administrators and payors alike, said the company.

Login
Username:

Password: